Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.

Abstract

Spasmodic dysphonia is a disabling voice condition caused by a chronic neurological disorder of central motor processing. Present therapy is directed at relief of symptoms rather than cure. Botulinum toxin type A injection into the thyroarytenoid muscle has become the pre-eminent approach for treatment of adductor spasmodic dysphonia. Botulinum toxin A injections can be performed in an out-patient setting under electromyographic guidance. We present our experience with 153 injections in 14 patients with adductor spasmodic dysphonia over a 10-year period. We demonstrate that the electromyography signal is a reliable prognostic indicator in terms of efficacy, and that patients' subjective opinion is a valid indicator of treatment success and future treatment strategy.

• Authors: P Casserly, C Timon
• Journal: The Journal of laryngology and otology (J Laryngol Otol) Vol. 122 Issue 1 Pg. 52-6 (Jan 2008) ISSN: 1748-5460 [Electronic] England
• PMID: 17470307 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Neuromuscular Agents
• Botulinum Toxins, Type A

Topics

• Adult
• Aged
• Botulinum Toxins, Type A (administration & dosage, therapeutic use)
• Dose-Response Relationship, Drug
• Electromyography
• Female
• Humans
• Injections, Intramuscular (methods)
• Male
• Middle Aged
• Neuromuscular Agents (administration & dosage, therapeutic use)
• Treatment Outcome
• Voice Disorders (drug therapy, physiopathology)